Quadrivalent adjuvanted haemagglutinin nanoparticle influenza vaccine: a step towards better protection of older adults from the constantly mutating H3N2 influenza viruses

Lancet Infect Dis. 2022 Jan;22(1):7-8. doi: 10.1016/S1473-3099(21)00209-7. Epub 2021 Sep 23.

Authors

Irina Isakova-Sivak¹, Victoria Matyushenko²

Affiliations

¹ Department of Virology, Institute of Experimental Medicine, Saint Petersburg, 197376 Russia. Electronic address: isakova.sivak@iemspb.ru.
² Department of Virology, Institute of Experimental Medicine, Saint Petersburg, 197376 Russia.

PMID: 34563276
DOI: 10.1016/S1473-3099(21)00209-7

No abstract available

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Age Factors
Aged
Antibodies, Viral / blood*
Humans
Influenza A Virus, H3N2 Subtype / genetics
Influenza A Virus, H3N2 Subtype / immunology*
Influenza A Virus, H3N2 Subtype / pathogenicity
Influenza Vaccines / administration & dosage
Influenza Vaccines / immunology*
Influenza, Human / immunology
Influenza, Human / prevention & control*
Mutation*
Nanoparticles / administration & dosage*
Nanoparticles / chemistry
Vaccine Potency

Substances

Adjuvants, Immunologic
Antibodies, Viral
Influenza Vaccines